Guaranteeing patient access by insourcing production of key material. A small facility that makes its own proteins from stockpiled lysate and locally amplified DNA changes who controls supply.
Stockpiled lysate and local DNA: supply becomes a policy choice, not a vendor’s.
Losing one facility can discontinue a therapy. Reserving domestic capacity for a bespoke bloodstream of molecules stays unaffordable while strain engineering repeats per molecule.
Lysa's process runs from lysate that can be stockpiled and DNA that can be amplified locally — so no single overseas supplier stands between a country and a protein medicine.
Tell us the supply gap you need to close — molecule classes, volumes, dependencies.